Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$21.65 +6.2%	$19.99	$14.40 ▼ $47.00	$1.35B	1.33	941,105 shs	891,177 shs
DVAX Dynavax Technologies	$9.91 +1.4%	$10.23	$9.22 ▼ $14.63	$1.17B	1.06	2.16 million shs	1.10 million shs
EBS Emergent Biosolutions	$6.76 +3.6%	$5.91	$4.02 ▼ $15.10	$353.89M	2.1	1.76 million shs	1.06 million shs
INVA Innoviva	$20.68 -0.7%	$19.51	$15.95 ▼ $22.00	$1.31B	0.37	675,047 shs	777,676 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	+6.18%	+7.93%	+6.39%	+10.63%	-40.14%
DVAX Dynavax Technologies	+1.43%	-0.80%	+1.12%	-27.03%	-13.07%
EBS Emergent Biosolutions	+3.62%	+8.36%	+5.56%	+30.63%	+0.31%
INVA Innoviva	-0.67%	-3.54%	+9.01%	+18.71%	+29.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.783 of 5 stars	4.4	3.0	0.0	2.7	0.0	0.0
DVAX Dynavax Technologies	4.2542 of 5 stars	3.3	1.0	4.7	2.5	1.7	1.9
EBS Emergent Biosolutions	4.2899 of 5 stars	3.5	2.0	4.6	1.4	2.5	1.3
INVA Innoviva	4.2128 of 5 stars	3.5	0.0	4.2	3.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	131.46% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	142.18% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	112.16% Upside
INVA Innoviva	3.00	Buy	$55.00	165.96% Upside

Current Analyst Ratings Breakdown

Latest EBS, CLDX, INVA, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
4/17/2025	DVAX Dynavax Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$12.00 ➝ $10.00
4/1/2025	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	204.72	N/A	N/A	$11.26 per share	1.92
DVAX Dynavax Technologies	$277.25M	4.29	$0.16 per share	61.70	$4.54 per share	2.18
EBS Emergent Biosolutions	$1.04B	0.35	$1.99 per share	3.39	$8.91 per share	0.76
INVA Innoviva	$358.71M	3.62	$3.40 per share	6.08	$11.03 per share	1.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	20.22	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.26	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
INVA Innoviva	$23.39M	-$1.01	N/A	13.34	N/A	-16.15%	15.77%	8.41%	7/29/2025 (Estimated)

Latest EBS, CLDX, INVA, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	21.67	21.67
DVAX Dynavax Technologies	0.49	11.93	10.84
EBS Emergent Biosolutions	1.20	6.32	3.51
INVA Innoviva	0.40	2.48	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
EBS Emergent Biosolutions	78.40%
INVA Innoviva	99.12%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
DVAX Dynavax Technologies	2.98%
EBS Emergent Biosolutions	3.20%
INVA Innoviva	2.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	52.54 million	Optionable
INVA Innoviva	100	62.78 million	61.36 million	Optionable

EBS, CLDX, INVA, and DVAX Headlines

Recent News About These Companies

First Week of August 15th Options Trading For Innoviva (INVA)

June 24 at 7:23 PM | nasdaq.com

Innoviva (NASDAQ:INVA) Ratio Stays Despite Growth Signs Nasdaq Composite

June 23 at 11:43 PM | kalkinemedia.com

SG Americas Securities LLC Makes New $737,000 Investment in Innoviva, Inc. (NASDAQ:INVA)

June 21, 2025 | marketbeat.com

CWA Asset Management Group LLC Increases Stake in Innoviva, Inc. (NASDAQ:INVA)

June 20, 2025 | marketbeat.com

Exchange Traded Concepts LLC Grows Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)

June 17, 2025 | marketbeat.com

Innoviva (NASDAQ:INVA) Hits New 12-Month High - Should You Buy?

June 16, 2025 | marketbeat.com

Promising Market Opportunity for Theravance Biopharma: Buy Rating on Ampreloxetine’s Potential in MSA Treatment

June 16, 2025 | tipranks.com

FDA to Review Novel Oral Antibiotic for Uncomplicated Gonorrhea

June 10, 2025 | empr.com

Innoviva Specialty's gonorrhea antibiotic to undergo FDA review

June 10, 2025 | msn.com

Innoviva Specialty Therapeutics Announces Acceptance Of Zoliflodacin NDA For Review

June 10, 2025 | kalkinemedia.com

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

June 10, 2025 | businesswire.com

Innoviva: A Riddle Wrapped In A Mystery Inside An Enigma

June 8, 2025 | seekingalpha.com

GAMMA Investing LLC Acquires 77,145 Shares of Innoviva, Inc. (NASDAQ:INVA)

June 7, 2025 | marketbeat.com

Innoviva (NASDAQ:INVA) Sets New 1-Year High - Time to Buy?

June 6, 2025 | marketbeat.com

Theravance Biopharma’s Hold Rating: Balancing Cash Influx with Long-term Growth Uncertainty

June 5, 2025 | tipranks.com

Theravance Biopharma Sells Trelegy Royalty Interest to GSK

June 2, 2025 | tipranks.com

Nuveen Asset Management LLC Has $5.32 Million Position in Innoviva, Inc. (NASDAQ:INVA)

June 1, 2025 | marketbeat.com

Two Sigma Investments LP Has $4.56 Million Stock Position in Innoviva, Inc. (NASDAQ:INVA)

May 29, 2025 | marketbeat.com

Jefferies Financial Group Inc. Has $5.14 Million Stake in Innoviva, Inc. (NASDAQ:INVA)

May 28, 2025 | marketbeat.com

Two Sigma Advisers LP Lowers Stock Position in Innoviva, Inc. (NASDAQ:INVA)

May 28, 2025 | marketbeat.com

Innoviva, Inc. (NASDAQ:INVA) Stock Holdings Lifted by Millennium Management LLC

May 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS, CLDX, INVA, and DVAX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$21.65 +1.26 (+6.18%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$22.16 +0.52 (+2.38%)

As of 06/24/2025 07:11 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$9.91 +0.14 (+1.43%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$9.79 -0.12 (-1.17%)

As of 04:43 AM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Emergent Biosolutions NYSE:EBS

$6.76 +0.24 (+3.62%)

Closing price 06/24/2025 03:59 PM Eastern

Extended Trading

$6.76 +0.00 (+0.04%)

As of 08:03 AM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Innoviva NASDAQ:INVA

$20.68 -0.14 (-0.67%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$20.55 -0.13 (-0.62%)

As of 04:05 AM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time